Cover Image
市場調查報告書

類肉瘤病 : 開發平台分析

Sarcoidosis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 200487
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
類肉瘤病 : 開發平台分析 Sarcoidosis - Pipeline Review, H1 2016
出版日期: 2016年03月16日 內容資訊: 英文 42 Pages
簡介

淋巴結和肺,肝臟,眼球,皮膚等組織的隆起、腫脹就稱之為類肉瘤病。類肉瘤病對人體的所有組織皆有可能,最初為肺和淋巴結上面的肉芽腫。類肉瘤病的成因雖然尚未解明,但主要的共通症狀有呼吸困難和咳嗽、皮疹、臉·手臂·脛上紅色隆起(結節性紅斑),眼睛發炎等。同時也會伴隨有體重減輕及倦怠感、盜汗,高熱等。治療的主要目的有保持肺和其他感染人體組織的正常運作,緩和症狀。目前除了利用皮質類固醇藥物來抑止發炎、形成肉芽腫之外,尚有利用Chloroquine、D- penicillamine、Chlorambucil、Methotrexate等。

本報告提供全球各國治療類肉瘤病所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

類肉瘤病概要

治療藥的開發

  • 類肉瘤病開發中產品:概要
  • 類肉瘤病開發中產品:比較分析

各企業正在開發的類肉瘤病治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

類肉瘤病治療藥:開發中的產品一覽(各企業)

類肉瘤病治療藥的開發企業

  • Araim Pharmaceuticals Inc.
  • Celgene Corporation
  • FirstString Research, Inc.
  • Novartis AG
  • PharmaIN Corporation

類肉瘤病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • ABS-11
  • apremilast
  • canakinumab
  • CC-220
  • cibinetide
  • eprodisate disodium
  • PGC-VIP
  • Synthetic Peptide for Sarcoidosis

類肉瘤病治療藥:最新的藥物簡介

類肉瘤病治療藥:暫停開發的產品

類肉瘤病治療藥:中止開發的產品

類肉瘤病相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7796IDB

Summary

Global Markets Direct's, 'Sarcoidosis - Pipeline Review, H1 2016', provides an overview of the Sarcoidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcoidosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
  • The report reviews pipeline therapeutics for Sarcoidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sarcoidosis therapeutics and enlists all their major and minor projects
  • The report assesses Sarcoidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sarcoidosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sarcoidosis Overview
  • Therapeutics Development
    • Pipeline Products for Sarcoidosis - Overview
  • Sarcoidosis - Therapeutics under Development by Companies
  • Sarcoidosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Sarcoidosis - Products under Development by Companies
  • Sarcoidosis - Companies Involved in Therapeutics Development
    • Araim Pharmaceuticals, Inc.
    • FirstString Research, Inc.
    • PharmaIN Corporation
  • Sarcoidosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABS-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cibinetide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eprodisate disodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Sarcoidosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sarcoidosis - Recent Pipeline Updates
  • Sarcoidosis - Dormant Projects
  • Sarcoidosis - Discontinued Products
  • Sarcoidosis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA
      • Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy
      • Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring
      • Oct 10, 2013: Araim Pharmaceuticals' ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sarcoidosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Sarcoidosis - Pipeline by Araim Pharmaceuticals, Inc., H1 2016
  • Sarcoidosis - Pipeline by FirstString Research, Inc., H1 2016
  • Sarcoidosis - Pipeline by PharmaIN Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Sarcoidosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Sarcoidosis - Dormant Projects, H1 2016
  • Sarcoidosis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Sarcoidosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top